Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24734786 | 0.79 | PTPN1 (0.61) | KDM4EALDH1A1GLAGAAHSD17B10 | |
| SCHEMBL2427657 | 0.73 | KDM4E (1.00) | KDM4ESMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL18631335 | 0.72 | KDM4E (1.00) | KDM4ESMN1; SMN2ALDH1A1GLAGAA | |
| Hydrochloric Acid SCHEMBL30228536 | 0.71 | KDM4E (0.96) | KDM4ESMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL28665936 | 0.71 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL3547426 | 0.70 | KDM4E (0.49) | KDM4ESMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL21836069 | 0.70 | KDM4E (0.79) | KDM4ESMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL7207846 | 0.70 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL29013081 | 0.69 | KDM4E (0.54) | KDM4ESMN1; SMN2ALDH1A1GLAGAA | |
| SCHEMBL10806873 | 0.69 | KDM4E (0.58) | KDM4ESMN1; SMN2ALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720881-B9 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | SPIROGEN SARL (CH) | 2013-04-17 | — | — | EP | disclosed |
| EP-1720881-B8 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | SPIROGEN SARL (CH) | 2013-01-16 | — | — | EP | disclosed |
| EP-1720881-B1 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | SPIROGEN LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| EP-2270010-B1 | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins | SPIROGEN LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| JP-2011157367-A | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4] BENZODIAZEPINE-5-ONE DERIVATIVE AS KEY INTERMEDIATE FOR PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINE | SPIROGEN LTD | 2011-08-18 | — | — | JP | disclosed |
| EP-2270010-A1 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | Spirogen Limited (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-7741319-B2 | 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20070173497-A1 | 11-Hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| EP-1720881-A1 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | Spirogen Limited (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085251-A1 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173497-A1 | 11-Hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines | H1-10, DRD1, SBDS | KDM4E 1229/4885SMN1; SMN2 1810/4885ALDH1A1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.